Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
Syndax Pharmaceuticals, Inc. – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – –…
Revenue Growth and Strategic …
Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full…